SEQUENTIAL TREATMENT STRATEGY FOR METASTATIC COLORECTAL CANCER: A PHASE III PROSPECTIVE RANDOMIZED MULTICENTER STUDY OF CHEMOTHERAPY (CT) WITH OR WITHOUT BEVACIZUMAB AS FIRST-LINE THERAPY FOLLOWED BY TWO PHASE III RANDOMIZED STUDIES OF CT ALONE OR CT PLUS BEVACIZUMAB WITH OR WITHOUT CETUXIMAB AS SECOND-LINE THERAPY. ITACa: Italian Trial in Advanced Colorectal Cancer

Trial Profile

SEQUENTIAL TREATMENT STRATEGY FOR METASTATIC COLORECTAL CANCER: A PHASE III PROSPECTIVE RANDOMIZED MULTICENTER STUDY OF CHEMOTHERAPY (CT) WITH OR WITHOUT BEVACIZUMAB AS FIRST-LINE THERAPY FOLLOWED BY TWO PHASE III RANDOMIZED STUDIES OF CT ALONE OR CT PLUS BEVACIZUMAB WITH OR WITHOUT CETUXIMAB AS SECOND-LINE THERAPY. ITACa: Italian Trial in Advanced Colorectal Cancer

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 01 Jul 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Cetuximab; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms ITACa
  • Most Recent Events

    • 27 Jun 2017 Planned End Date changed from 1 Mar 2017 to 1 Mar 2018.
    • 06 Jun 2017 Results (n=370) assessing efficacy of bevacizumab in second-line versus first-line treatment of metastatic colorectal cancer, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 28 Sep 2016 Planned End Date changed from 1 Mar 2016 to 1 Mar 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top